


Claims

1. A compound represented by the formula (I)



- 5 wherein ring B represents a cyclic hydrocarbon group which may have substituent(s); Z represents hydrogen atom or a cyclic group which may have substituent(s); R^1 represents hydrogen atom, a hydrocarbon group which may have substituent(s), a heterocyclic group which may have
- 10 substituent(s) or an acyl group; R^2 represents amino group which may have substituent(s); D represents a bond or a divalent group; E represents a bond, $-CO-$, $-CON(R^a)-$, $-COO-$, $-N(R^a)CON(R^b)-$, $-N(R^a)COO-$, $-N(R^a)SO_2-$, $-N(R^a)-$, $-O-$, $-S-$, $-SO-$ or $-SO_2-$ (R^a and R^b each independently represents
- 15 hydrogen atom or a hydrocarbon group which may have substituent(s)); G represents a bond or a divalent group; L represents a bond or a divalent group; A represents hydrogen atom or a substituent; X and Y each represents hydrogen atom or an independent substituent; and represents that
- 20 R^2 and an atom on ring B may form a ring, or a salt thereof.

2. The compound according to claim 1, wherein E is

-CO-, -CON(R^a)-, -COO-, -N(R^a)CON(R^b)-, -N(R^a)COO-, -N(R^a)SO₂-, -N(R^a)-, -O-, -S-, -SO- or -SO₂- (R^a and R^b each independently represents hydrogen atom or a hydrocarbon group which may have substituent(s)).

- 5 3. The compound according to claim 1, wherein L is
- (1) a bond or,
 - (2) a divalent hydrocarbon group which may contain -O- or -S- and may possess 1 to 5 substituents selected from
 - i) a C₁₋₆ alkyl group,
 - 10 ii) a halogeno-C₁₋₆ alkyl group,
 - iii) phenyl group,
 - iv) benzyl group,
 - v) amino group which may have substituent(s),
 - vi) hydroxy group which may have substituent(s), and
 - 15 vii) carbamoyl groups or thiocarbamoyl groups which each may be substituted by:
 - a) a C₁₋₆ alkyl group,
 - b) a phenyl group which may have substituent(s), or
 - c) a heterocyclic group which may have substituent(s).

- 20 4. The compound according to claim 1, wherein Z is a cyclic group which may have substituent(s).

5. The compound according to claim 1, wherein D is a divalent group bonded to the ring through a carbon atom.

6. The compound according to claim 1, wherein ring
- 25 B is benzene ring which may have substituent(s) and L is a C₁₋₆ alkylene group.

7. The compound according to claim 1, wherein G represents a divalent hydrocarbon group which may have substituent(s) and ring B does not form a ring together with

R².

8. The compound according to claim 1, wherein A is hydrogen atom, ring B is benzene ring, Z is a phenyl group substituted by a halogen, and R¹ is a C₁₋₆ alkyl or C₇₋₁₄ aralkyl group which each may be substituted by substituent(s) selected from (1) hydroxy, (2) phenyl, (3) a C₁₋₆ alkyl carbonyl or a C₆₋₁₄ aryl-carbonyl, and (4) amino groups which may be substituted by a C₁₋₆ alkyl sulfonyl or a C₆₋₁₄ aryl-sulfonyl.

10 9. The compound according to claim 1, wherein X and Y each independently is hydrogen atom, a halogen, hydroxy, a C₁₋₆ alkoxy, a halogeno-C₁₋₆ alkoxy, a C₇₋₁₄ aralkyloxy, a benzoyl-C₁₋₆ alkoxy, a hydroxy-C₁₋₆ alkoxy, a C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkoxy, a C₃₋₁₄ cycloalkyl-C₁₋₆ alkoxy, an
15 imidazol-1-yl-C₁₋₆ alkoxy, a C₇₋₁₄ aralkyloxy-carbonyl-C₁₋₆ alkoxy, or a hydroxyphenyl-C₁₋₆ alkoxy;

ring B is benzene ring which may be substituted by a C₁₋₆ alkoxy, or tetrahydroisoquinoline ring or isoindoline ring which is formed by combination with R²;

20 Z is a C₆₋₁₄ aryl group, a C₃₋₁₀ cycloalkyl group, piperidyl group, thienyl group, furyl group, pyridyl group, thiazolyl group, indanyl group or indolyl group which may have 1 to 3 substituents selected from a halogen, formyl, a halogeno-C₁₋₆ alkyl, a C₁₋₆ alkoxy, a C₁₋₆ alkyl-carbonyl,
25 oxo and pyrrolidinyl;

A is hydrogen atom;

D is a C₁₋₆ alkylene group;

G is a bond, or a C₁₋₆ alkylene group which may contain phenylene and may be substituted by phenyl;

R^1 is hydrogen atom, a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{6-14} aryl group or a C_{7-14} aralkyl group which each may be substituted by substituent(s) selected from (1) a halogen, (2) nitro, (3) amino which may have 1 or 2 substituents selected from a C_{1-6} alkyl which may be substituted by a C_{1-6} alkyl-carbonyl, benzoyloxycarbonyl and a C_{1-6} alkylsulfonyl, (4) hydroxy which may be substituted by (i) a C_{1-6} alkyl which may be substituted by hydroxy, a C_{1-6} alkyl-carbonyl, carboxy or a C_{1-6} alkoxy-carbonyl, (ii) phenyl which may be substituted by hydroxy, (iii) benzoyl or (iv) a mono- or di- C_{1-6} alkylamino-carbonyl, (5) a C_{3-6} cycloalkyl, (6) phenyl which may be substituted by hydroxy or a halogeno- C_{1-6} alkyl and (7) thienyl, furyl, thiazolyl, indolyl or benzyloxycarbonylpiperidyl;

R^2 is (1) unsubstituted amino group, (2) piperidyl group or (3) amino which may have 1 or 2 substituents selected from (i) benzyl, (ii) a C_{1-6} alkyl which may be substituted by amino or phenyl, (iii) a mono- or di- C_{1-6} alkyl-carbamoyl, or a mono- or di- C_{1-6} alkyl-thiocarbamoyl, (iv) a C_{1-6} alkoxy-carbonyl, (v) a C_{1-6} alkyl-sulfonyl, (vi) piperidylcarbonyl and (vii) a C_{1-6} alkyl-carbonyl which may be substituted by a halogen or amino;

E is a bond, $-\text{CON}(R^a)-$, $-\text{N}(R^a)\text{CO}-$, $-\text{N}(R^a)\text{CON}(R^b)-$ (R^a and R^b each represents hydrogen atom or a C_{1-6} alkyl group);

L is a C_{1-6} alkylene group which may contain -O- and may be substituted by a C_{1-6} alkyl.

10. The compound according to claim 1, wherein X and Y each independently is hydrogen atom, a halogen, hydroxy or a C_{1-6} alkoxy;

ring B is benzene ring or, by combination with R^2 , tetrahydroisoquinoline ring or isoindoline ring;

Z is phenyl group which may be substituted by a halogen, D is a C_{1-6} alkylene group, G is a C_{1-6} alkylene group;

5 R^1 is a C_{1-6} alkyl group or a C_{7-14} aralkyl group which each may be substituted by substituent(s) selected from (1) hydroxy, (2) phenyl and (3) amino which may be substituted by a C_{1-6} alkyl-carbonyl or a C_{1-6} alkylsulfonyl;

R^2 is unsubstituted amino group;


10 E is -CONH-;

L is a C_{1-6} alkylene group.

11. A prodrug of the compound according to claim 1 or a salt thereof.

12. A process for producing a compound of the formula


15 (I-a)



(I-a)


[wherein the symbols have the same meanings as described above] or a salt thereof which comprises:

reacting a compound represented by the formula (IIa)




(IIa)

[wherein R^{2a} represents amino group which may be protected and substituted, and other symbols have the same meanings as described in claim 1], a reactive derivative thereof or
 5 a salt thereof, with a compound represented by the formula



[wherein the symbols have the same meanings as described in the claim 1] or a salt thereof to produce a compound of the formula (Ia-a)



(Ia-a)

[wherein the symbols have the same meanings as described above] or a salt thereof, and optionally, subjecting it to

de-protecting reaction.


13. A pharmaceutical composition which comprises a compound according to claim 1 or a salt thereof.

14. A pharmaceutical composition according to claim 13 which is a somatostatin receptor function regulator.

15. A pharmaceutical composition according to claim 14 wherein the somatostatin receptor function regulator is a somatostatin receptor agonist.

16. A pharmaceutical composition according to claim 13 which is an agent for preventing or treating diabetes, obesity, diabetic complications or intractable diarrhea.


17. A method for regulating a somatostatin receptor function which comprises administering a compound represented by the formula (I)



[wherein ring B represents a cyclic hydrocarbon group which may have substituent(s); Z represents hydrogen atom or a cyclic group which may have substituent(s); R^1 represents hydrogen atom, a hydrocarbon group which may have substituent(s), a heterocyclic group which may have substituent(s) or an acyl group; R^2 represents amino group which may have substituent(s); D represents a bond or a

divalent group; E represents a bond, -CO-, -CON(R^a)-, -COO-,
 -N(R^a)CON(R^b)-, -N(R^a)COO-, -N(R^a)SO₂-, -N(R^a)-, -O-, -S-,
 -SO- or -SO₂- (R^a and R^b each independently represents
 hydrogen atom or a hydrocarbon group which may have
 5 substituent(s)); G represents a bond or a divalent group;
 L represents a bond or a divalent group; A represents hydrogen
 atom or a substituent; X and Y each represents hydrogen atom
 or an independent substituent; and represents that
 R² and an atom on ring B may form a ring] or a salt thereof.

10 18. Use of a compound represented by the formula (I)



[wherein ring B represents a cyclic hydrocarbon group which
 may have substituent(s); Z represents hydrogen atom or a
 cyclic group which may have substituent(s); R¹ represents
 15 hydrogen atom, a hydrocarbon group which may have
 substituent(s), a heterocyclic group which may have
 substituent(s) or an acyl group; R² represents amino group
 which may have substituent(s); D represents a bond or a
 divalent group; E represents a bond, -CO-, -CON(R^a)-, -COO-,
 20 -N(R^a)CON(R^b)-, -N(R^a)COO-, -N(R^a)SO₂-, -N(R^a)-, -O-, -S-,
 -SO- or -SO₂- (R^a and R^b each independently represents
 hydrogen atom or a hydrocarbon group which may have

substituent(s)); G represents a bond or a divalent group;
L represents a bond or a divalent group; A represents hydrogen
atom or a substituent; X and Y each represents hydrogen atom
or an independent substituent; and represents that
5 R² and an atom on ring B may form a ring] or a salt thereof,
for manufacturing a medicament for regulating a somatostatin
receptor function.